
Speaking on- Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP): MFS and DFS, but not EFS, are Valid Surrogate Endpoints for Overall Survival.

RadOnc Conference Room
UH B2C430
Contact Samantha Harbacuk
Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/254184086
Join the conference call:
734-997-7110 @ prompt press 3103#
If you have any issues please contact Steven Jordan
New to GoToMeeting? Get the app now and be ready when your first meeting starts: https://global.gotomeeting.com/install/254184086
Meredith M Regan, ScD, Assoc. Professor: Harvard Medical School & Dana-Farber Cancer Institute
Speaking on- Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP): MFS and DFS, but not EFS, are Valid Surrogate Endpoints for Overall Survival.